Code raises a series A to develop Duchenne and diabetes therapies June 7, 2022 By Lee Landenberger Code Biotherapeutics Inc. has raised an upsized and oversubscribed series A financing to develop programs for treating rare and genetic diseases that include Duchenne muscular dystrophy and type 1 diabetes.Read More
New cytokine inhibitors patented by Peptinov SAS, Conservatoire National des Arts et Metiers June 7, 2022
Cytoplasmic RNA vector expressing anti-CD81 antibodies suppresses experimental arthritis May 31, 2022
New non-receptor tyrosine-protein kinase TYK2 inhibitors described by PharmaBlock Sciences May 17, 2022
RSS
